| abstract |
The present invention relates to compounds of the formula (I) in which R 1 is phenyl optionally substituted by halogen, lower alkyl, lower cycloalkyl, lower alkoxy, cyano, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, substituted lower alkoxy by halogen or lower alkoxy substituted by hydroxy; or is pyridin-2-, -3- or -4-yl optionally substituted by halogen, lower alkyl, lower cycloalkyl, cyano, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, lower alkoxy, lower alkoxy substituted by halogen or alkoxy lower substituted by hydroxyl; or is pyrimidin-2-, -4- or -5-yl optionally substituted by halogen, lower alkyl, lower cycloalkyl, lower alkyl substituted by hydroxy or lower alkyl substituted by halogen; or is pyrazin-2-yl optionally substituted by halogen, lower alkyl, lower cycloalkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy or cyano; or is 2,2-difluorbenzo [d] [1,3] dioxol-5-yl, or is thiazolyl optionally substituted by lower alkyl substituted by halogen; R2 is hydrogen or lower alkyl; R3 is hydrogen, amino or lower alkyl; Z is a bond, - CH2- or -O-; or to a pharmaceutically appropriate acid addition salt thereof. It has now been found that the compounds of formulas I have a good affinity with the receptors associated with trace amines (TAAR), especially with TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders , Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, consumption disorders and energy assimilation, disorders and malfunction of temperature homeostasis body, sleep and circadian rhythm disorders and cardiovascular disorders. |